In collaboration with DT Consulting, Carenity*, part of EvidentIQ, conducted a survey of patients whose primary condition was ankylosing spondylitis, bipolar disorder, breast cancer, chronic obstructive pulmonary disease, depression, diabetes, multiple sclerosis, Parkinson’s disease, or rheumatoid arthritis,  to see if pharma channels are performing well enough for patients.

As patients seek to become more informed and involved in their own healthcare, their health outcomes are closely tied to the pharmaceutical industry’s ability to engage with them. To assess the current state of this relationship, we surveyed patients in Europe and the U.S. so that our partner DT Consulting could put patients in the role of customer and applied our Customer Experience Quotient® (CXQ®) metric to see which CX efforts satisfied or disappointed patients.

In particular, we asked the patient:

What did you do when you last engaged with pharma-created services or information?

How do you most prefer to interact with pharmaceutical firms, and what kind of interaction do you actually have most often?

What was the most recent pharma-created service or information you used?

After your last engagement with pharma-created services or information, what did you do?

How did your most recent interaction with a pharmaceutical company affect your view of the following?

Has COVID-19 made you more or less likely to engage with pharma in the future?

Access the complete report

*What is Carenity?

Carenity by EvidentIQ is our leading social platform supporting +500,000 patients and caregivers worldwide, across +1,200 chronic and rare diseases. Carenity provides direct, timely and compliant access to patient real-world data. Our Carenity platforms help fulfill our unique offer for Real-World Evidence, Clinical Trial Optimization, as well as Scientific Communication and Publications.

Carenity connects people suffering from the same conditions by providing them with a free social network: friends, newsfeed, discussion forums, private messaging, etc. We are convinced that new technologies help members feel less alone and better informed.

Find out more.

In collaboration with DT Consulting, Carenity*, part of EvidentIQ, conducted a survey of patients from France, Germany, Italy, Spain, the UK, and the US to learn more about their experience with clinical trials.

Understanding the difference between participants’ expectations and their actual experiences is a key issue in advancing medical research.

What are patients’ expectations in terms of communication from the organization managing the clinical trial during a clinical trial?
How is the patient informed about the trial? And by which health actor first?
What channels of communication does the patient use most with the organization managing the clinical trial?
What factors have the most impact on a patient’s decision to complete a clinical trial?

Access the complete report

*What is Carenity?

Carenity by EvidentIQ is our leading social platform supporting +500,000 patients and caregivers worldwide, across +1,200 chronic and rare diseases. Carenity provides direct, timely and compliant access to patient real-world data. Our Carenity platforms help fulfill our unique offer for Real-World Evidence, Clinical Trial Optimization, as well as Scientific Communication and Publications.

Carenity connects people suffering from the same conditions by providing them with a free social network: friends, newsfeed, discussion forums, private messaging, etc. We are convinced that new technologies help members feel less alone and better informed.

Find out more.

PatientLive® is a unique solution that allows to quickly survey an online community of 500,000 patients and caregiversstudies

Paris (FRANCE), 25.10.2021. Today EvidentIQ announced that its PatientLive® software is opening its doors to the clinical market. The PatientLive® platform grants access to real-time insights and reliable answers from patients and caregivers through quick polls.

PatientLive® was created by Carenity, part of the EvidentIQ group, in 2016 with the purpose of offering pharma companies a unique and fast way to get access to real-time patient insights. The Carenity team believes that guesswork is no longer enough but knows that time is also valuable. Therefore PatientLive® allows to collect real-time patient insights at a fast pace, in order to help make better strategic decisions regarding clinical patient-centric projects.
Carenity’s mission is to bring patient perspective into clinical projects to accelerate clinical trials, save costs and ensure the success of new products. With this revolutionary software, the life science industry can leverage real-time patient insights at each phase of the clinical development like early R&D, Clinical development, Clinical operations, Patient engagement, and Medical affairs.

PatientLive® can help understand patient experience (burden, Quality of life) to define Target Product Profiles, evaluate patient’s acceptance of protocol evaluation parameters and flow chart, incorporate study endpoints that are valuable from a patient perspective, optimize the design of clinical trials to facilitate patient recruitment and retention, identify preliminary feasibility for clinical projects, ensure study materials are patient-centric and easy to understand (ICF testing), and test concepts of services and tools to increase patient retention on clinical trials.

Michael Chekroun, Chief Strategy and Transformation Officer at the EvidentIQ group and Founder of Carenity, tells us about this offering:

“PatientLive® has always offered quick responses and has been characterized for its simplicity and autonomy of use. We want now to make this available for the clinical markets and keep this virtuous circle of Data for Good going.”

More about PatientLive®

PatientLive® is a unique solution that allows to quickly survey an online community of 500,000 patients and caregivers in the US and Europe with up to 36 conditions available, letting users acquire real-time insights via a five-question poll. Five types of questions including images and videos are available: single choice, multiple choice, 0 to 5 scale, text field, and numeric field. Polls on PatientLive® initiate patients data generation on topics including: disease/treatment burden, unmet needs, quality of life, services and communication message testing, and information and service needs. These early insights are invaluable for PatientLive® users as they enable better patient-centric solutions and materials and may guide the development of further non-observational studies and Real World Evidence projects.

Contact us for more information on PatientLive® by EvidentIQ.

I’m Gilda Teissier, Marketing Director at EvidentIQ and I recently met with Emilie Pain, Data Scientist at Carenity, part of the EvidentIQ Group.

Whether to develop new products, services, design clinical trials or marketing strategies, first-hand access to patients and caregivers is increasingly becoming a cornerstone for life sciences industries.

By collaborating and engaging with patients in the decision-making process, health providers can make better decisions regarding a patient’s health. Therefore, having access to accurate information reported by patients and caregivers is essential to understand patient experience and be patient-centric, identify unmet needs in terms of products, services and information, test concepts of services and campaign messages, define Target Product Profiles, and optimize the design of clinical trials (study materials, endpoints, protocol assessment).

The only problem sometimes is that having access to this information can take time and a lot of resources. PatientLive® is a platform that responds to this by giving access to real-time Insights in a fast, autonomous and simple way.

Today I have the pleasure to interview Emilie Pain, PatientLive® Product Manager. She will help us understand better the need of patient-centric information and how PatientLive® helps us meet that in a quick and accurate way.

Gilda: Which are the main challenges of healthcare providers when it comes to access and use of patient information?

Emilie: Access to information directly reported by patients is long and complex for healthcare providers due to regulatory constraints. They need a third party that allows them to have quick access to patient insights on a regular basis to understand patient experience, to test new materials, and to listen to patient expectations and thus create patient-centric materials.

Gilda: What is PatientLive®?

Emilie: PatientLive® is a unique solution that allows customers to quickly survey an online community of 500,000 patients and caregivers in the US and Europe via quick polls (1 to 5 questions).

“PatientLive® is a unique solution that allows customers to quickly survey an online community of 500,000 patients and caregivers in the US and Europe via quick polls”

This tool, unique on the market, provides access to accurate patient insights in a compliant way. It also allows our customers to target specific patient profiles (country, condition, addition of a screener question).

The polls implemented through this platform allow quick and easy access to patient insights, which are complementary to traditional marketing surveys or real-world studies (non-interventional studies, preference studies, etc.) conducted by Carenity.

Gilda: Who is PatientLive® for?

Emilie: PatientLive® is a solution dedicated to the life sciences industry, such as pharmaceutical companies, biotech companies, medtechs or healthtechs companies. It can be of special interest to market research/business insights, commercial/marketing, patient engagement, medical affairs, market access, research and development, clinical development, and clinical operations teams.

Finally, it can also help consulting firms, market research agencies, and communication agencies to support the life sciences industry in their strategic decisions and actions.

This solution is available in the US and Europe (France, the United Kingdom, Germany, Spain and Italy).

Gilda: Which conditions can be targeted?

Emilie: PatientLive® is available for 36 conditions. These conditions include oncology, such as breast cancer or lung cancer, but also immunology (e.g. rheumatoid arthritis, multiple sclerosis, lupus), respiratory (e.g. Asthma, COPD), endocrinology (e.g. type 1 diabetes, type 2 diabetes, obesity), gastroenterology (e.g. Crohn’s disease), dermatology (e.g. psoriasis), etc. A detailed list can be found at the PatientLive’s site.

Gilda: How does it work?

Emilie: Once a customer has defined a topic, they can implement their poll on the platform.

PatientLive® offers the possibility to ask up to 5 questions per poll. There are 5 types of questions available: single choice, multiple choice, scale from 0 to 5, text field, numeric field and test of images/videos.

PatientLive® offers the possibility to ask up to 5 questions per poll.

They can also create a screener question to target a sub-population. A screener question is a question to which the answer must be either «Yes» or «No». For example, a screener question can be “Are you treated by insulin therapy?”. Only the respondents who choose «Yes» as answer are considered at the display of the results.

Once the poll has been created, a validation is made by the Carenity’s Data Science team before the poll goes live.

Then, invitations to participate are sent to patients and poll results are available once the first respondent has answered. 

Gilda: How much time does it take to obtain results and how are they delivered?

Emilie: The period can vary from 1 to 15 days, depending on the condition, the screening questions and the targeted number of respondents.

The results are available in real time on the site. Starting from the first responses customers can visualize the results thanks to our dashboard. Our customers also have the possibility to download the results (raw data, tables of results, or report) in real time.

Gilda: Can you give us a specific example of how the results can be integrated by pharmaceutical companies?  

Emilie: The results of a PatientLive® poll can be integrated by pharmaceutical companies through different ways, but one of the most concrete examples we have is from a poll we conducted among diabetic patients which evaluated a new advertising campaign and allowed our customer to adjust the wording of this campaign. I can also think of polls conducted to better understand patient experience (disease/treatment burden, quality of life), to identify patients’ unmet needs in terms of products, services and information, or to measure patients’ perception of products, devices or services.

Gilda: Are there any specificities in the use of the data by clinical teams or CROs?

Emilie: The results of a poll can support clinical teams in the definition of the Target Product Profile, in the evaluation of patient’s acceptance of the protocol evaluation parameters and flow chart, in the definition of study endpoints valuable from a patient perspective, in the optimization of the design of the clinical trial, etc. For instance, we have recently conducted a poll evaluating patient understanding of the information notice that was planned to be used on a clinical trial. It helped our customer clarify some parts of this information notice. 

Gilda: You previously mentioned that consulting firms, market research agencies, and communication agencies can also use PatientLive®. What are the type of polls they conduct?

Emilie: They mainly use our tool to differentiate their proposal and pitch by incorporating patient insights, to assess the feasibility of their studies, to optimize the design and the questionnaire of their patient studies, to generate patient insights to enrich their results and recommendations, and to test concepts of services or campaigns. To give a more specific example, a poll was conducted among breast cancer patients in order to evaluate the proportion per stage and thus the feasibility to conduct a study among metastatic breast cancer.  

Gilda: Thanks a lot for your time!

For more information about PatientLive® click here.